



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 6 Aug 2019 (#25)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- **National Institute of Mental Health (NIMH) notice on Clinical Trials Policies NOT-MH-19-031.** NIMH supports clinical trials in the following manner
 - Studies primarily focused on testing or confirming Efficacy/Effectiveness/Safety of an intervention may be submitted to [NIMH-specific Clinical Trials RFAs](#)
 - Selected Funding Opportunity Announcements (FOAs) that allow clinical trials applications (i.e., designated as either “Clinical Trials Optional” or “Clinical Trials Required”)
- **Notice of System Change and Procedure for Requesting an Extension to Early Stage Investigator (ESI) Status NOT-OD-19-125 .** The new ESI extension request process will be integrated into the eRA Commons for streamlined and secure access.
- **Request for Information (RFI): Swallowable Smart Pills or Devices to Enable Precision Nutrition, Microbiome and Gastroenterological Research NOT-DK-19-020** The purpose of this Request for Information (RFI) is to solicit public input to inform efforts aimed at advancing the development of and accessibility to devices that enable clinical gastroenterological procedures on awake individuals and research on dietary components-host interactions and gut microbiota ecology in discrete gastrointestinal (GI) regions, with the focus on advancing host-diet microbial interactions. The information respondents provide will help characterize what technologies are currently available to facilitate the study of discrete regions of the human GI tract as well as identify key priorities and recommendations for future research efforts.
- **National Institute of General Medical Sciences (NIGMS) Priorities for Sepsis Research NOT-GM-19-054.** The purpose of this notice is to inform potential applicants to the National Institute of General Medical Sciences (NIGMS) of areas of sepsis research that are of special interest to the Institute. NIGMS is interested in receiving applications that will provide new knowledge of the mechanistic complexity of sepsis in humans and that will test strategies for translating this knowledge into improved diagnostics and therapies for sepsis patients.
- **Notice of Data Sharing Policy for the National Institute of Mental Health NOT-MH-19-041.** This Notice clarifies the timeline related to NIMH data sharing Notices. [NOT-MH-19-033](#) goes into effect for all applications submitted after January 1, 2020. Notices [NOT-MH-06-108](#), [NOT-MH-09-005](#), [NOT-MH-14-015](#), and [NOT-MH-15-012](#) remain in effect until January 1, 2020. On that date, all four of those notices will be rescinded.
- **Fast Healthcare Interoperability Resources (FHIR®) Standard NOT-OD-19-122** The purpose of this notice is to encourage NIH researchers to explore the use of the Fast Healthcare Interoperability Resources (FHIR®) standard to capture, integrate, and exchange clinical data for research purposes and to enhance capabilities to share research data.

- **Request for Information (RFI): Regarding Bioinformatics/Computational Needs for National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Investigators Engaged in Diabetes, Endocrinology and Metabolic Diseases Research** [NOT-DK-19-024](#) NIDDK invites interested investigators to provide input on their needs for bioinformatics/computational support to advance R01-based research in Diabetes, Endocrinology and Metabolic Diseases. Through this Request for Information (RFI), the NIDDK seeks information from the scientific community about specific bioinformatics and/or computational support that may be scarce or lacking, and that is needed to advance, translate, and accelerate research into causes and consequences of diabetes and other related endocrine or metabolic diseases. The information obtained will aid the NIDDK in future programming of resources to support the research community in these areas.
- **Notice of National Cancer Institute (NCI) participation on** [PAR-19-326](#), **Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care in Low and Middle-Income Countries (R21 Clinical Trial Optional)** [NOT-CA-19-066](#)

1. (Re)Building a Kidney (UC2 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-19-007](#)

Type: [UC2](#)

Application Due Date: November 7, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA invites new applications for the (Re)Building a Kidney (RBK) Consortium. The goal of the RBK is to improve or restore failing kidney function after injury or disease. This FOA invites teams of investigators with complementary expertise to develop and test novel ways to either (1) stimulate productive kidney repair/regeneration in vivo, or (2) generate functional kidney tissue ex vivo for transplantation.

Budget: [NIDDK](#) intends to commit \$3.6M in FY 2020 to fund 4 awards. Application budgets are expected to be no more than \$500,000 in direct costs and reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. National Institute of Diabetes, Digestive and Kidney Diseases Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-319](#)

Type: [X01](#)

Application Due Date: October 31, 2019; March 3, 2020; June 30, 2020, October 27, 2020; March 2, 2021; June 29, 2021; October 26, 2021; March 1, 2022; June 28, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at <https://repository.niddk.nih.gov>. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability

Budget: No funds are provided. The total number of approvals for access is dependent on the number of meritorious applications and the availability of the requested non-renewable samples. The maximum project period is 3 years.

3. Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-325](#)

Type: [R01](#)

Application Due Date: September 30, 2019; February 11, 2020; September 30, 2020; February 11, 2021; September 20, 2021; February 11, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-326](#)

Type: R21

Application Due Date: November 12, 2019, November 12, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/co-infections, d) reducing the effects of stigma on, and/or by, family members or caregivers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project.

5. Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-327](#)

Type: U01

Application Due Date: Applications will be accepted on a rolling basis, beginning on August 26, 2019. Applications received by January 1, 2020 will be reviewed by April 1, 2020; Applications received by May 1, 2020 will be reviewed by August 1, 2020; Applications received by September 1, 2020 will be reviewed by December 1, 2020; Applications received by January 1, 2021 will be reviewed by April 1, 2021; Applications received by May 1, 2021 will be reviewed by August 1, 2021; Applications received by September 1, 2021 will be reviewed by December 1, 2021; Applications received by January 1, 2022 will be reviewed by April 1, 2022; Applications received by May 1, 2022 will be reviewed by August 1, 2022; Applications received by September 1, 2022 will be reviewed by December 1, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to \$5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code. Applications will be handled on an expedited review and award basis to meet the goals of this program.

Budget: NIH intends to fund an estimate of 2-3 awards per year. Application budgets are limited to \$5 million per year for direct costs. The maximum period of support is 3 years.

6. Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-ES-19-011](#)

Type: R21

Application Due Date: November 1, 2019; December 2, 2019; January 2, 2020; February 3, 2020; March 2, 2020; April 1, 2020; May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021; June 1, 2021; July 1, 2021; August 2, 2021; September 1, 2021; October 1, 2021; November 1, 2021; December 1, 2021; January 3, 2022; February 1, 2022; March 1, 2022; April 1, 2022; May 2, 2022; June 1, 2022; July 1, 2022; August 1, 2022; September 1, 2022; October 3, 2022. No late applications will be accepted for this Funding Opportunity Announcement. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

Budget: NIEHS intends to commit \$800,000 per year for fiscal years 2020, 2021, 2022, 2023 to fund 4-5 awards each year. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the 2-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizel*
e: lizelk@sun.ac.za | t: +27 21 808 2105